Payment overview · 2025
General Payments
$1,773.15
82 reported records · 20 companies
Healthcare provider profile · identity verified
Lawrence Amato, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · GRAYSLAKE, IL · NPI 1528020690
Verified facts
What the public records show
CMS Open Payments records show Lawrence Amato, M.D. received $1,773.15 in general payments during 2025 across 82 reported records.
AstraZeneca Pharmaceuticals LP accounted for 14.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 38 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Linzess, Mounjaro, Ozempic, Rybelsus, Trintellix.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 161 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 248 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 583 claims for Eliquis by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 98 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 248 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 85 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 97 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 583 claims for Eliquis by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Trintellix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $264.11 | 14.9% | 13 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $192.79 | 10.9% | 9 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $187.80 | 10.6% | 12 | 2025 |
| Alpha Cognition USA, Inc. | Unresolved — no canonical attribution shown | $161.34 | 9.1% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $139.81 | 7.9% | 5 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $102.70 | 5.8% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $100.50 | 5.7% | 5 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $82.48 | 4.7% | 4 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $81.31 | 4.6% | 4 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $81.09 | 4.6% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $78.43 | 4.4% | 4 | 2025 |
| Electromed, Inc. | Unresolved — no canonical attribution shown | $60.19 | 3.4% | 5 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $54.09 | 3.0% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $41.71 | 2.4% | 2 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $36.81 | 2.1% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $29.29 | 1.6% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $24.15 | 1.4% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $24.08 | 1.4% | 1 | 2025 |
| IBSA Pharma Inc. | Unresolved — no canonical attribution shown | $16.06 | 0.9% | 1 | 2025 |
| Echosens North America, Inc. | Unresolved — no canonical attribution shown | $14.41 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,773.15 | 82 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Zunveyl Normalized: zunveyl |
Drug | Alpha Cognition USA, Inc. | $161.34 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $102.70 | 4 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $91.77 | 5 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $87.67 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $86.26 | 4 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $82.48 | 4 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $81.09 | 4 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $80.79 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $80.79 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $71.48 | 3 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $67.38 | 4 | 2025 |
Source payment records
|
|||||
| TEZSPIRE Normalized: tezspire |
Biological | AstraZeneca Pharmaceuticals LP | $63.01 | 3 | 2025 |
Source payment records
|
|||||
| SMARTVEST Normalized: smartvest |
Device | Electromed, Inc. | $60.19 | 5 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $57.48 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $55.08 | 3 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $54.09 | 2 | 2025 |
Source payment records
|
|||||
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $52.66 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $52.29 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $39.75 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $39.75 | 2 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $38.68 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $36.99 | 3 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $36.81 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $35.81 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $34.17 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $31.77 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $29.29 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $24.15 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $24.08 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $23.24 | 1 | 2025 |
Source payment records
|
|||||
| FASENRA Normalized: fasenra |
Biological | AstraZeneca Pharmaceuticals LP | $22.25 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $18.47 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $18.47 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $18.04 | 1 | 2025 |
Source payment records
|
|||||
| Flector Normalized: flector |
Drug | IBSA Pharma Inc. | $16.06 | 1 | 2025 |
Source payment records
|
|||||
| Licart Normalized: licart |
Drug | IBSA Pharma Inc. | $16.06 | 1 | 2025 |
Source payment records
|
|||||
| Tirosint Normalized: tirosint |
Drug | IBSA Pharma Inc. | $16.06 | 1 | 2025 |
Source payment records
|
|||||
| Fibroscan Normalized: fibroscan |
Device | Echosens North America, Inc. | $14.41 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 583 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 161 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 248 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 40 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 76 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 35 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRINTELLIX trintellix |
2025 | Trintellix | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
70 | 19 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
161 | 19 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
36 | 11 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
248 | 36 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
583 | 55 |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
98 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
248 | 36 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
76 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
85 | 13 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
97 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
35 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
68 | 66 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
583 | 55 |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 2094 | 181 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1762 | 180 |
| Furosemide | Furosemide | 1346 | 113 |
| Pantoprazole Sodium | Pantoprazole Sodium | 1034 | 112 |
| Amlodipine Besylate | Amlodipine Besylate | 1027 | 116 |
| Sertraline Hcl | Sertraline Hcl | 944 | 63 |
| Metformin Hcl | Metformin Hcl | 880 | 101 |
| Memantine Hcl | Memantine Hcl | 859 | 54 |
| Trazodone Hcl | Trazodone Hcl | 832 | 43 |
| Gabapentin | Gabapentin | 795 | 79 |
| Quetiapine Fumarate | Quetiapine Fumarate | 760 | 36 |
| Metoprolol Tartrate | Metoprolol Tartrate | 737 | 71 |
| Tamsulosin Hcl | Tamsulosin Hcl | 727 | 60 |
| Potassium Chloride | Potassium Chloride | 697 | 62 |
| Metoprolol Succinate | Metoprolol Succinate | 673 | 84 |
| Lisinopril | Lisinopril | 666 | 74 |
| Escitalopram Oxalate | Escitalopram Oxalate | 600 | 39 |
| Eliquis | Apixaban | 583 | 55 |
| Lorazepam | Lorazepam | 552 | 41 |
| Clopidogrel | Clopidogrel Bisulfate | 501 | 53 |
| Tramadol Hcl | Tramadol Hcl | 492 | 83 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 475 | 100 |
| Donepezil Hcl | Donepezil Hcl | 469 | 26 |
| Methylprednisolone | Methylprednisolone | 344 | 204 |
| Alprazolam | Alprazolam | 343 | 49 |
| Losartan Potassium | Losartan Potassium | 327 | 51 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 298 | 52 |
| Prednisone | Prednisone | 296 | 51 |
| Carvedilol | Carvedilol | 285 | 34 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 283 | 12 |
| Simvastatin | Simvastatin | 272 | 44 |
| Mirtazapine | Mirtazapine | 271 | 23 |
| Alendronate Sodium | Alendronate Sodium | 268 | 28 |
| Azithromycin | Azithromycin | 248 | 153 |
| Jardiance | Empagliflozin | 248 | 36 |
| Fluoxetine Hcl | Fluoxetine Hcl | 242 | 17 |
| Divalproex Sodium | Divalproex Sodium | 218 | 18 |
| Spironolactone | Spironolactone | 216 | 24 |
| Duloxetine Hcl | Duloxetine Hcl | 213 | 18 |
| Allopurinol | Allopurinol | 212 | 37 |
| Levetiracetam | Levetiracetam | 208 | 13 |
| Pregabalin | Pregabalin | 197 | 13 |
| Clonazepam | Clonazepam | 196 | 13 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 187 | 72 |
| Ezetimibe | Ezetimibe | 182 | 24 |
| Omeprazole | Omeprazole | 181 | 45 |
| Pravastatin Sodium | Pravastatin Sodium | 178 | 31 |
| Farxiga | Dapagliflozin Propanediol | 161 | 19 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 156 | 29 |
| Aripiprazole | Aripiprazole | 155 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 155 | 15 |
| Amoxicillin | Amoxicillin | 154 | 99 |
| Warfarin Sodium | Warfarin Sodium | 145 | 16 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 144 | 76 |
| Atenolol | Atenolol | 141 | 26 |
| Risperidone | Risperidone | 141 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 136 | 39 |
| Nabumetone | Nabumetone | 135 | 39 |
| Meloxicam | Meloxicam | 131 | 15 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 128 | 23 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 126 | 60 |
| Hydrochlorothiazide | Hydrochlorothiazide | 123 | 28 |
| Bupropion Xl | Bupropion Hcl | 121 | 14 |
| Buspirone Hcl | Buspirone Hcl | 113 | suppressed |
| Digoxin | Digoxin | 113 | 18 |
| Amiodarone Hcl | Amiodarone Hcl | 106 | suppressed |
| Tradjenta | Linagliptin | 103 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 100 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 99 | 12 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 98 | 49 |
| Xarelto | Rivaroxaban | 98 | 22 |
| Entresto | Sacubitril/Valsartan | 97 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 95 | 54 |
| Montelukast Sodium | Montelukast Sodium | 91 | 18 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 90 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 90 | 20 |
| Benztropine Mesylate | Benztropine Mesylate | 88 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 87 | 35 |
| Gemfibrozil | Gemfibrozil | 86 | suppressed |
| Trulicity | Dulaglutide | 85 | 13 |
| Bumetanide | Bumetanide | 84 | suppressed |
| Januvia | Sitagliptin Phosphate | 84 | 11 |
| Valsartan | Valsartan | 83 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 82 | 15 |
| Torsemide | Torsemide | 80 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 78 | 24 |
| Mounjaro | Tirzepatide | 76 | 13 |
| Baclofen | Baclofen | 74 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 71 | suppressed |
| Fluconazole | Fluconazole | 70 | 17 |
| Synthroid | Levothyroxine Sodium | 70 | 19 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 69 | 28 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 68 | 66 |
| Glimepiride | Glimepiride | 68 | 12 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 66 | 24 |
| Ropinirole Hcl | Ropinirole Hcl | 66 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 64 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 64 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 63 | 27 |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 63 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 63 | 15 |
| Oxybutynin Chloride | Oxybutynin Chloride | 61 | suppressed |
| Cephalexin | Cephalexin | 60 | 39 |
| Clarithromycin | Clarithromycin | 60 | 32 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 57 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 57 | 11 |
| Olanzapine | Olanzapine | 57 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 57 | suppressed |
| Celecoxib | Celecoxib | 56 | 11 |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 56 | suppressed |
| Movantik | Naloxegol Oxalate | 56 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 53 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 52 | suppressed |
| Finasteride | Finasteride | 51 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 51 | 15 |
| Irbesartan | Irbesartan | 51 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 51 | 20 |
| Methocarbamol | Methocarbamol | 51 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 50 | suppressed |
| Myrbetriq | Mirabegron | 50 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 49 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 49 | 22 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 49 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 48 | suppressed |
| Glipizide | Glipizide | 48 | suppressed |
| Topiramate | Topiramate | 46 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 45 | 16 |
| Clozapine | Clozapine | 44 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 44 | 15 |
| Lovastatin | Lovastatin | 43 | 13 |
| Lurasidone Hcl | Lurasidone Hcl | 43 | suppressed |
| Novolog Flexpen | Insulin Aspart | 43 | 13 |
| Nystatin | Nystatin | 43 | 24 |
| Vascepa | Icosapent Ethyl | 43 | suppressed |
| Anastrozole | Anastrozole | 42 | suppressed |
| Cefepime Hcl | Cefepime Hcl | 41 | suppressed |
| Famotidine | Famotidine | 41 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 41 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 41 | 21 |
| Linzess | Linaclotide | 40 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 39 | suppressed |
| Methotrexate | Methotrexate Sodium | 39 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 39 | suppressed |
| Telmisartan | Telmisartan | 38 | 11 |
| Symbicort | Budesonide/Formoterol Fumarate | 36 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 36 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 35 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 35 | 13 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 35 | suppressed |
| Ozempic | Semaglutide | 35 | 11 |
| Vancomycin Hcl | Vancomycin Hcl | 35 | suppressed |
| Latanoprost | Latanoprost | 34 | suppressed |
| Levofloxacin | Levofloxacin | 34 | 22 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 34 | suppressed |
| Lactulose | Lactulose | 32 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 32 | suppressed |
| Xifaxan | Rifaximin | 30 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 29 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 28 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Roflumilast | Roflumilast | 27 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 26 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 26 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 26 | suppressed |
| Diazepam | Diazepam | 25 | suppressed |
| Trulance | Plecanatide | 25 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 24 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 24 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 24 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 24 | suppressed |
| Rybelsus | Semaglutide | 24 | suppressed |
| Amantadine | Amantadine Hcl | 23 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 23 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 23 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 23 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 23 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 22 | suppressed |
| Kapspargo Sprinkle | Metoprolol Succinate | 22 | suppressed |
| Lamotrigine | Lamotrigine | 22 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 22 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 21 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 21 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 21 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 21 | suppressed |
| Colchicine | Colchicine | 20 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 20 | suppressed |
| Sucralfate | Sucralfate | 20 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 20 | suppressed |
| Verapamil Er | Verapamil Hcl | 20 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 19 | suppressed |
| Ramipril | Ramipril | 19 | suppressed |
| Chlorthalidone | Chlorthalidone | 18 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 18 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Ibuprofen | Ibuprofen | 18 | suppressed |
| Indomethacin | Indomethacin | 18 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 17 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 16 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 16 | suppressed |
| Clomipramine Hcl | Clomipramine Hcl | 16 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 16 | suppressed |
| Phenobarbital | Phenobarbital | 16 | suppressed |
| Silodosin | Silodosin | 16 | suppressed |
| Testosterone | Testosterone | 16 | suppressed |
| Trimethoprim | Trimethoprim | 16 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 15 | suppressed |
| Eszopiclone | Eszopiclone | 15 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Repatha Sureclick | Evolocumab | 15 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 15 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 14 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 14 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 14 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 14 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 13 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 13 | suppressed |
| Glipizide Er | Glipizide | 13 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 13 | suppressed |
| Metronidazole | Metronidazole | 13 | suppressed |
| Mirabegron Er | Mirabegron | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 13 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 13 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 12 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 12 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Methadone Intensol | Methadone Hcl | 12 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 12 | suppressed |
| Piperacillin-Tazobactam | Piperacillin Sodium/Tazobactam | 12 | suppressed |
| Sotalol | Sotalol Hcl | 12 | suppressed |
| Fentanyl | Fentanyl | 11 | suppressed |
| Fluphenazine Decanoate | Fluphenazine Decanoate | 11 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 11 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,773.15 · 82 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, Auvelity, BREZTRI, COBENFY, CREON, ELIQUIS, FARXIGA, FASENRA, FREESTYLE LIBRE 3, Fibroscan, Flector, IBSRELA, JARDIANCE, KISUNLA, KRYSTEXXA, Kerendia, Korlym, LEQVIO, LINZESS, Licart, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, QULIPTA, REPATHA, Rybelsus, SMARTVEST, SPRAVATO, TEZSPIRE, TRINTELLIX, Tirosint, UBRELVY, VRAYLAR, Wegovy, ZAVZPRET, ZEPBOUND, Zunveyl | 16 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error